Guselkumab en HS

Published in Dermatology

Journal Scan / Case Study · March 08, 2020

Successful Use of Guselkumab in the Treatment of Severe Hidradenitis Suppurativa

Clinical and Experimental Dermatology

TAKE-HOME MESSAGE

• A 28-year-old woman with a history of hidradenitis suppurativa (HS) since age 8 continued to have active skin disease despite treatment with metformin, spironolactone, and surgical intervention. The patient also had a history of latent tuberculosis (TB), treated with 6 months of rifampin.

• The patient was started on guselkumab due to her history of TB. After 12 weeks of treatment, she reported significant improvement in pain as well as resolution of all active HS lesions. After discontinuing her metformin and spironolactone, disease control was sustained at 24 weeks.

– Caitlyn T. Reed, MD

Abstract

Hidradenitis suppurativa (HS) is a chronic incurable disease of apocrine gland-bearing skin characterised by double comedones, recurrent nodules, draining tracts and scarring predominantly in the axilla, groin and inframammary folds. Adalimumab and Infliximab are recommended for use in HS Hurley stage 2-3 and there are several reported cases and one case series of successful treatment with Ustekinumab which blocks the p40 subunit of IL-12 and IL-231 . We report a case of successful treatment of HS with a monoclonal antibody (Guselkumab) to the p19 subunit of IL-23.

Clinical and Experimental Dermatology

Successful Use of Guselkumab in the Treatment of Severe Hidradenitis Suppurativa

Clin Exp Dermatol 2020 Feb 18;[EPub Ahead of Print], N Kearney, N Byrne, B Kirby, R Hughes

Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 4000-1054
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.